

Prévention des infections nosocomiales en réanimation



Dr Philippe Eggimann, PD&MER
Service de Médecine Intensive Adulte
www.soins-intensifs-chuv.ch



icine 1999

septembre 2010 n° 1984

taux

Aurélie Janet-Vendreau,
externe en chirurgie
thoracique à
l'Hôtel-Dieu, à Paris.

« Conflits d'intérêts » : Martin Hirsch accuse

**Les 50 meilleurs
dans 30 spécialités
La vérité sur les
tarifs dans le public**

RELIQUE : 5 €
EXPRESS-ROULETTE
M 01722 - J0065 - F: 3,90 €

L'équipe de la clinique Sourdille
à Nantes, n°1 pour la chirurgie
de la rétine et de la cataracte.

mieux répertoriées, sa
CHU accueillent les

Le monde des infections nosocomiales

SwissDRG SA
Haslerstrasse 21
CH-3008 Berne
Tél. ++41 31 310 05 50
Fax ++41 31 310 05 57
E-Mail info@swissdrg.org



Exigences SwissDRG :

- SwissDRG SA se fonde sur les recommandations de H+ concernant les clés d'imputations des coûts indirects. L'hôpital doit respecter au moins le critère minimal REKOLE.


Le tableau ci-dessous liste les principaux centres de charges. Suivez-vous au minimum la clé minimale recommandée par REKOLE ? Si oui, cochez les cases qui conviennent :

Centre de charges obligatoire	Bloc de coûts	Clé minimale
Pas de compensation pour les infections nosocomiales		
26 Procédé d'imagerie médicale	Coûts primaires et secondaires	☐ Point de taxe ou Minute*
31 Corps médicaux	Domaines d'activités 1 à 5 ³ (Coûts primaires et secondaires)	☐ Point de taxe (TARMED: PM et PT) ou Minut
	Domaines d'activités 6 ³ (Coûts primaires et secondaires)	☐ Point de taxe (TARMED: PM uniquement) o Minute
39 Services de soins	Coûts primaires et secondaires	☐ Minute
41 Hôtellerie - chambres	Coûts primaires et secondaires	☐ Journée d'hospitalisation
1 Administration des patients	Coûts primaires et secondaires	☐ Cas administratif



Le monde des infections nosocomiales

Prévalence: méthodologie




Séjours hospitaliers

Infections nosocomiales


Le monde des infections nosocomiales

Prévalence 7.2% (4.2%-10.5%)

7783 patients
629 infections





The world of nosocomial infections



The world of nosocomial infections


After adjustment for case-mix





The world of infections


1'265 worldwide ICU
14'414 patients
51% with infection
(08.05.2007)



EPIC II study
Vincent JAMA 2009


The world of nosocomial infections

1'265 worldwide ICU
14'414 patients



EPIC II study
Vincent JAMA 2009

The world of nosocomial infections




Adapted from: Richards CCM 1999; Eggimann Chest 2001; Chim Burns 2007

Le monde des infections nosocomiales

Prévalence des infections nosocomiales

G. Zanetti, L. Senn, C. Petignat, SMMPH




Impact of nosocomial infections

Crude mortality
30% to 60%

Attributable mortality
0% to 40%

Prolongation of length of stay
5 to 25 days

Increase of costs
5,000 to 40,000 euros



Impact of nosocomial sepsis

SwissDRG SA
Haslerstrasse 21
CH-3008 Berne
Tél. ++41 31 310 05 50
Fax ++41 31 310 05 57
E-Mail info@swissdrg.org

DRG

Exigences SwissDRG :

- SwissDRG SA se fonde sur les recommandations de H+ concernant les clés d'imputations des coûts indirects. L'hôpital doit respecter au moins le critère minimal REKOLE.

Le tableau ci-dessous liste les principaux centres de charges. Suivez-vous au minimum la clé minimale recommandée par REKOLE ? Si oui, cochez les cases qui conviennent :


Centre de charges obligatoire	Bloc de coûts	Clé minimale
No compensation for nosocomial infection		
31 Corps médicaux	Domaines d'activités 1 à 5 ¹ (Coûts primaires et secondaires)	☐ Point de taxe (TARMED: PM et PT) ou Minute
	Domaines d'activités 6 ² (Coûts primaires et secondaires)	☐ Point de taxe (TARMED: PM uniquement) ou Minute
39 Services de soins	Coûts primaires et secondaires	☐ Minute
41 Hôtellerie - chambres	Coûts primaires et secondaires	☐ Journée d'hospitalisation
1 Administration des patients	Coûts primaires et secondaires	☐ Cas administratif

Impact



Wey et al. Arch Intern Med 1988; Voss et al. Infection 1997
Eggimann et al. Chest 2001; Blot et al. Am J Med 2002

Nous devons les prévenir !!



Strategies for infection control

General measures

Surveillance

Isolation precautions

Antibiotic control

Restriction of use, guidelines, rotation


Selective digestive decontamination

Specific measures

Specifically targeted against VAP


Specifically targeted against BSI

Specifically targeted against



Caveats for surveillance of NI in the ICU

Routine collection, tabulation, analysis and feedback of information on the occurrence of NI



Essential before planning any intervention

Strategies for infection control

General measures

Surveillance

Isolation precautions

Antibiotic control

Restriction of use, guidelines, rotation


Selective digestive decontamination

Specific measures


Specifically targeted against VAP

Specifically targeted against BSI


Specifically targeted against



Principles of isolation precautions




Principles of isolation precautions



The objective is not to isolate but
to prevent the
TRANSMISSION
of microorganisms


Physiopathologie des infections nosocomiales



Physiopathologie des infections nosocomiales




Physiopathologie des infections nosocomiales



to prevent


contact

TRANSMISSION




Evidence-based model for hand transmission during patient care and the role of improved practices

Didier Pittet, Benedetta Allegranzi, Hugo Sax, Sasi Dharan, Carmem Lúcia Pessoa-Silva, Liam Donaldson, John M Boyce; on behalf of the WHO Global Patient Safety Challenge, World Alliance for Patient Safety



to prevent





Compliance to Hand Hygiene

Time constraint = major obstacle for hand hygiene




handwashing

1 to 1.5 min

alcohol-based
hand rub


15 to 20 sec

Average duration of hand hygiene by HCW




Pittet and Boyce, Lancet Infectious Diseases 2001

Average duration of hand hygiene by HCW




Les 5 indications de l'hygiène des mains



Au 12: 53 distributeurs pour 14 lits !

Hygiène en ré

L'observance au SMIA unités 1 et 2 (78%) est supérieure à l'observance globale du CHUV en 2013 (71%).



Au 12: 53 distributeurs pour 14 lits !

Strategies for infection control

General measures

Surveillance

Isolation precautions

Antibiotic control

Restriction of use, guidelines, rotation


Selective digestive decontamination


Specific measures

Specifically targeted against VAP

Specifically targeted against BSI

Specifically targeted against





Isolation precautions

Standard precautions

dailywork



dailywork




dailywork




dailywork



dailywork



Standard precautions



Isolation precautions

Transmission-based precautions



exceptions

FOR MRSA



MRSA au CHUV
Objectif
zéro transmission
à l'hôpital!

[En savoir plus >](#)

Standard precautions

dailywork



dailywork




dailywork



dailywork




dailywork



Worldwide leader of nosocomial infection

1'265 worldwide ICU - 14'414 patients (08.05.2007)
51% with infection



1012 MSSA (90% nosocomial)
507 MRSA (95% nosocomial)

EPIC II study
Vincent JAMA 2009


MRSA is everywhere !!!




MRSA is everywhere !!!

25 MRSA positive patients isolated in single-rooms


% of positive screening





MRSA is everywhere !!!



Service de détection: SIA - Médecine intensive adulte (SMIA)



L'objectif n'est pas d'isoler !




Mais de prévenir la transmission
des microorganismes






Service de détection: SIA - Médecine intensive adulte (SMIA)




Screening + preemptive isolation + decolonization may control MRSA




**Isolement
préemptif**

**Test
rapide**




**Isolement
préemptif**

**Test
rapide**



Vancomycin-resistant enterococci (VRE)




Vancomycin-resistant enterococci (VRE)




Transfer of Vancomycin-Resistant Enterococci via Health Care Worker Hands

Amy N. Duckro, DO; Donald W. Blom, RN; Elizabeth A. Lyle, AB; Robert A. Weinstein, MD; Mary K. Hayden, MD



Risk of Hand or Glove Contamination After Contact With Patients Colonized With Vancomycin-Resistant *Enterococcus* or the Colonized Patients' Environment

Mary K. Hayden, MD; Donald W. Blom, BSN; Elizabeth A. Lyle, AB;
Charity G. Moore, PhD; Robert A. Weinstein, MD



A PROSPECTIVE STUDY TO DETERMINE WHETHER COVER GOWNS IN ADDITION TO GLOVES DECREASE NOSOCOMIAL TRANSMISSION OF VANCOMYCIN-RESISTANT ENTEROCOCCI IN AN INTENSIVE CARE UNIT



Arjun Srinivasan, MD; Xiaoyan Song, MD, MS; Tracy Ross, BSc; William Merz, PhD; Roy Brower, MD; Trish M. Perl, MD, MSc

VRE acquisition rate
cases/100 days at risk

Gloves + gown 1.8

Gloves alone 3.8

OR 2.5 (1.2-5.3)

Vous êtes ici: [Accueil](#)

Recherche intranet

Annuaire téléphonique

Organigramme et unités

Applications sécurisées

Directives institutionnelles

Risques et accidents

Actualités

[\[voir toutes les actualités\]](#) - [\[soumettre\]](#)

FBM

Vous avez dit OGM? Tentez votre chance au QUIZ FBM de novembre

Publié le 05.11.2013

Concours est ouvert aux communautés UNIL et CHUV

Formation

Formation continue: CAS en Santé publique

Publié le 05.11.2013

Délai d'inscription au 15 décembre 2013. Inscrivez-vous!

Formation

Introduction à la transplantation d'organes

Publié le 05.11.2013

Cours post-gradué du 5 novembre 2013

Vie au CHUV

Recherche volontaires pour la JOM (14 novembre après-midi)

Publié le 05.11.2013

Le jeudi 14 novembre (après-midi) aura lieu la JOM. Nous recherchons des volontaires pour accompagner les groupes d'enfants dans les

Agenda

Exposition

Exposition Sandrine Pelletier, Bourse Alice Bailly

02.10.2013 | 18h30

Espace CHUV Hall principal

Exposition

Valérie Masson « Peintures et dessins »

31.10.2013 | 17h00

Galerie ERGASIA

Exposition

Art à la Maternité - Exposition

01.11.2013 | 17h30

Hall de la maternité du CHUV

Colloque

Colloque de médecine d'urgence

06.11.2013 | 13h00

Salle BH05-1120.

[Liste des intranets](#)[Liste des internets](#)**Je suis...**[...un nouveau collaborateur](#)**Accès rapides**[Prise en charge du patient](#)
[Techniques de soins](#)
[Messagerie Outlook](#)
[Disponibilité des applications](#)
[Direction générale](#)**Vie pratique****Ressources pour le personnel**






Mesures de base



et

Gouttelettes plus



+



Masque (FFP 2)

**Car risque élevé d'aérosolisation
lors des soins tels que:**

*aspirations, intubation, bronchoscopie,
VNI, RCP, frottis naso-pharyngés,
nébulisations, ventilation au masque,
soins de bouche, extubation, ...*



Dans la mesure du possible:

Box seul + pression négative > Box seul > Cohortage

Strategies for infection control

General measures

Surveillance

Isolation precautions

Antibiotic control

Restriction of use, guidelines, rotation


Selective digestive decontamination

Specific measures

Specifically targeted against VAP

Specifically targeted against BSI


Specifically targeted against





Source control ?

From traditional
soap and cloathes



To
disposable wipes



Source control ?

Chlorhexidine Gluconate to Cleanse Patients in a Medical Intensive Care Unit

Source Control to Reduce the Bioburden of Vancomycin-Resistant Enterococci


Bathed with soap and water

Skin Contamination

Environmental Contamination

Worker Hand Contamination

Patient Acquisition



Source control ?


Chlorhexidine Gluconate to Cleanse Patients in a Medical Intensive Care Unit

Source Control to Reduce the Bioburden of Vancomycin-Resistant Enterococci

Cleansed with chlorhexidine cloths




Bathed with soap and water



Source control ?

Prevention of Bloodstream Infections by Use of Daily Chlorhexidine Baths for Patients at a Long-Term Acute Care Hospital

L. Silvia Munoz-Price, MD; Bala Hota, MD, MPH; Alexander Stemer, MD; Robert A. Weinstein, MD




INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY NOVEMBER 2009, VOL. 30, NO. 11

The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant *Staphylococcus aureus*, vancomycin-resistant *Enterococcus*, and healthcare-associated bloodstream infections: Results of a quasi-experimental multicenter trial*

(Crit Care Med 2009; 37:1858-1865)

Michael W. Climo, MD; Kent A. Sepkowitz, MD; Gianna Zuccotti, MD, MPH; Victoria J. Fraser, MD; David K. Warren, MD; Trish M. Perl, MD, MSc; Kathleen Speck; John A. Jernigan, MD; Jaime R. Robles, PhD; Edward S. Wong, MD





Effectiveness of Routine Patient Cleansing with Chlorhexidine Gluconate for Infection Prevention in the Medical Intensive Care Unit

Kyle J. Popovich, MD; Bala Hota, MD, MPH; Robert Hayes, BA; Robert A. Weinstein, MD; Mary K. Hayden, MD

Effectiveness of Chlorhexidine Bathing to Reduce Catheter-Associated Bloodstream Infections in Medical Intensive Care Unit Patients

Susan C. Bleasdale, MD; William E. Trick, MD; Ines M. Gonzalez, MD; Rosie D. Lyles, MD; Mary K. Hayden, MD; Robert A. Weinstein, MD


Arch Intern Med. 2007;167(19):2073-2079



INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY OCTOBER 2009, VOL. 30, NO. 10

Source control ?

MICU patients colonized by *Acinetobacter baumannii*
daily 4%-CHX body wash



17% of pts
admitted
colonized

6% of pts
discharged
colonized

BSI 7.28

BSI 7.28

/1000 patients-days

/1000 patients-days



Quand l'ergonomie joue un tour à la toilette !

C. Joseph¹, V. Plouhinec¹, M.J. Thévenin², Ph. Maravic¹, Ph. Eggmann¹ (christine.joseph@chuv.ch)
 Service de Médecine Intensive Adulte¹, Service Médecine Préventive Hospitalière² CHUV, Lausanne, Suisse.



INTRODUCTION


La toilette : Un moment privilégié entre le patient et le soignant (détente, rafraîchissement), d'observation (état de la peau), d'évaluation sensitivomoteur (perception, toucher, stimuler), de communication et d'échange (ressenti, douleur, angoisse). Une configuration architecturale (1 lavabo par chambre de 2 à 3 lits) complique sa réalisation et favorise le risque de transmission de germes.

METHODE

Test de 4 types de lingettes (incontinence) et de gants (toilette) à usage unique. Questionnaire unique. Nombre de toilettes avec chaque produit.

RESULTATS

- 1) UN SEUL GESTE: lave, hydrate, et stimule
- 2) GAIN DE TEMPS: 10 min/toilette (équivalent à 1 EPT/an)
- 3) Observation continue du patient, sans interruptions
- 4) Gain de temps (pas de rinçage, ni de séchage, produit hydratant)
- 5) Meilleur respect des principes d'hygiène lors de la toilette
- 6) ↓ dangers: glissade, éclaboussures
- 7) Amélioration de nos pratiques
- 8) Diminution des trajets au lavabo



Evaluation de 4 lingettes et gants à usage unique au SMIA

	Produit 1 (n=61)	Produit 2 (n=56)	Produit 3 (n=34)	Produit 4 (n=14)	Total (n=165)
Satisfaction globale					
+++	51 (84%)	25 (45%)	9 (27%)	11 (79%)	96 (58%)
+	3 (5%)	26 (46%)	24 (70%)	3 (21%)	56 (34%)
-	6 (10%)	5 (9%)	1 (3%)	0	12 (7%)
---	1 (1%)	0	0	0	1 (0.5%)
Confort du soignant					
+++	47 (77%)	31 (55%)	6 (18%)	8 (56%)	92 (55%)
+	8 (14%)	24 (43%)	28 (82%)	5 (37%)	65 (38%)
-	5 (8%)	1 (2%)	0	1 (7%)	7 (4%)
---	1 (1%)	0	0	0	1 (0.5%)
Confort du patient					
Non évalué (sédaté)					
+++	13	36	31	5	85
+	17 (36%)	5 (25%)	0	5 (56%)	27 (34%)
-	16 (34%)	10 (50%)	3 (100%)	4 (44%)	33 (42%)
---	13 (29%)	5 (25%)	0	0	18 (23%)
---	1 (1%)	0	0	0	1 (1%)
Odeur du produit					
Non évalué (sédaté)					
+++	9	0	0	2	11
+	22 (42%)	52 (93%)	13 (38%)	10 (84%)	97 (63%)
-	24 (46%)	4 (7%)	21 (62%)	1 (8%)	50 (32%)
---	6 (12%)	0	0	1 (8%)	7 (5%)
---	0	0	0	0	0
Réaction cutanée					
Oui	0	0	0	0	0
non	61 (100%)	56 (100%)	34 (100%)	14 (100%)	165 (100%)




AVANTAGES : Gain ergonomique majeur (rapide et simple)

- Gain de temps : 10 min/toilette → 1 EPT/an
- Gain d'hygiène: ↓ opportunités de transmission des germes
- Gain d'efficacité: ↓ de va et vient, réduction du bruit, intimité
- Gain en confort: odeur et texture agréables
- Gain en sécurité: ↓ glissade, éclaboussure des pansements

INCONVENIENTS

- Température: malgré microonde, les derniers gants sont froids
- Pas possible de réchauffer un paquet utilisé (hygiène)
- Gants parfois pas assez humides. Gaspillage ?



CONCLUSIONS:

Satisfaction des soignants

Disparition des préjugés sur la « toilette sans eau »

Satisfaction des patients

Patients conscients apprécient: (toucher et odeur agréable), diminution des douleurs et des éclaboussures. long terme ?

Satisfaction de l'administrateur ?

Moins cher et plus efficace !

→ NOUS INTRODUISONS LES LINGETTES A USAGE UNIQUE

ORIGINAL ARTICLE


Effect of Daily Chlorhexidine Bathing on Hospital-Acquired Infection

Michael W. Climo, M.D., Deborah S. Yokoe, M.D., M.P.H., David K. Warren, M.D.,
Trish M. Perl, M.D., Maureen Bolon, M.D., Loreen A. Herwaldt, M.D.,
Robert A. Weinstein, M.D., Kent A. Sepkowitz, M.D., John A. Jernigan, M.D.,
Kakotan Sanogo, M.S., and Edward S. Wong, M.D.

CONCLUSIONS

Daily bathing with chlorhexidine-impregnated washcloths significantly reduced the risks of acquisition of MDROs and development of hospital-acquired bloodstream infections.

Effect of Daily Chlorhexidine Bathing on Hospital-Acquired Infection




ORIGINAL ARTICLE

Targeted versus Universal Decolonization to Prevent ICU Infection

Susan S. Huang, M.D., M.P.H., Edward Septimus, M.D., Ken Kleinman, Sc.D.,
Julia Moody, M.S., Jason Hickok, M.B.A., R.N., Taliser R. Avery, M.S.,
Julie Lankiewicz, M.P.H., Adrijana Gombosev, B.S., Leah Terpstra, B.A.,
Fallon Hartford, M.S., Mary K. Hayden, M.D., John A. Jernigan, M.D.,
Robert A. Weinstein, M.D., Victoria J. Fraser, M.D., Katherine Haffenreffer, B.S.,
Eric Cui, B.S., Rebecca E. Kaganov, B.A., Karen Lolans, B.S.,
Jonathan B. Perlin, M.D., Ph.D., and Richard Platt, M.D.,
for the CDC Prevention Epicenters Program and the AHRQ DECIDE Network
and Healthcare-Associated Infections Program*

C Bloodstream Infection from Any Pathogen



Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial

Lennie P G Derde, Ben S Cooper, Herman Goossens, Surbhi Malhotra-Kumar, Rob J L Willems, Marek Gniadkowski, Waleria Hryniewicz, Joanna Empel, Mirjam J D Dautzenberg, Djillali Annane, Irene Aragão, Annie Chalfine, Uga Dumpis, Francisco Esteves, Helen Giamarellou, Igor Muzlovic, Giuseppe Nardi, George L Petrikos, Viktorija Tomic, Antonio Torres Martí, Pascal Stammet, Christian Brun-Buisson*, Marc J M Bonten*, on behalf of the MOSAR WP3 Study Team

